Agalsidase Beta BS Intravenous Infusion 5mg “JCR”, containing Agalsidase beta (genetically recombined) [Agalsidase beta successor 1], is manufactured by JCR Pharma. This injectable drug, with YJ code 3959420A1029 and standard 5mg x 1 bottle, is an enzyme replacement therapy used for the treatment of Fabry disease.
Agalsidase Beta BS Intravenous Infusion 5mg “JCR”
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →